Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03254732
Other study ID # POLARIS2016-002
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date July 14, 2017
Est. completion date February 25, 2020

Study information

Verified date March 2020
Source Polaris Group
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase 1b, open label trial of ADI-PEG 20 (36 mg/m2) weekly in combination with pembrolizumab (1 and 2 mg/kg or 200 mg) every three weeks. Assessment of safety and tolerability of drug combination


Description:

This is an open-label, phase 1b trial of ADI-PEG 20 in combination with pembrolizumab in subjects with advanced cancers. Dose escalation will occur using a 3 + 3 + 3 design. The first subject in a dose escalation cohort must have had treatment with ADI-PEG 20 + pembrolizumab with a week of follow up) before the next 2 subjects are enrolled. Thus subjects 2 and 3 may be enrolled on day 8 if there is no dose limiting toxicity (DLT) in subject 1. No additional delay is required between treating subjects 4 to 6 or 7 to 9 in an expanded cohort. Before proceeding to the next cohort dose level, the first 3 eligible subjects in each cohort will have received at least 21 days of treatment (i.e. at least 2 of the expected 3 doses of ADI-PEG 20 + one dose of pembrolizumab).


Recruitment information / eligibility

Status Terminated
Enrollment 33
Est. completion date February 25, 2020
Est. primary completion date May 7, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Select Inclusion Criteria: 1. Histologically confirmed diagnosis of advanced solid tumor. 2. Prior failure of a systemic treatment approved by the health authority in the country where the study will be enrolling. Such subjects may also have been treated with radiotherapy, local therapy or surgery. 3. Measurable disease using RECIST 1.1 criteria. 4. Age = 18 years. Select Exclusion Criteria: 1. Subjects with history of another primary cancer, including co-existent second malignancy, with the exception of: a) curatively resected non-melanoma skin cancer; b) curatively treated cervical carcinoma in situ; or c) other primary solid tumor with no known active disease present or in the opinion of the investigator will not affect patient outcome. 2. Subjects who had been treated with ADI-PEG 20 previously. 3. History of seizure disorder not related to underlying cancer. 4. Known allergy to pegylated compounds. 5. Known allergy to E. coli drug products (such as GMCSF).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ADI PEG20
ADI is a recombinant protein cloned from M. hominis and produced in E. coli, and conjugated with PEG of 20,000 mw. Thus ADI-PEG 20 is an arginine degrading enzyme, ADI, coupled to PEG.
Pembrolizumab
Pembrolizumab is a PD-1 blocking antibody indicated in the USA for the treatment.

Locations

Country Name City State
Taiwan Facility National Cheng Kung University Tainan

Sponsors (1)

Lead Sponsor Collaborator
Polaris Group

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Other Overall Survival Follow-Up by Phone or Clinic Visit 12 months after end of treatment
Primary Number of Participants with Adverse Events as a Measure of Safety and Tolerability of ADI-PEG 20 in combination with Pembrolizumab in Advanced Solid Cancers Number of participants with treatment-related adverse events and severity this is graded by CTCAE and MedDRA for Coding Up to 36 months
Secondary Number of Participants with PFS with Combination ADI-PEG 20 and Pembro. Progression Free Survival determined by RECIST 1.1 Assessments ever 9 weeks for 12 months
Secondary Number of Participants with RR with Combination ADI-PEG 20 and Pembro. Response Rate determined by RECIST 1.1 Assessments ever 9 weeks for 12 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02792465 - A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors Phase 1
Terminated NCT00886782 - A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03956680 - An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers Phase 1
Completed NCT03512340 - Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers Phase 1
Terminated NCT00337376 - A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers Phase 1
Completed NCT00478101 - Opioid Rotation Versus Combination for Chronic Uncontrolled Cancer Pain Phase 2
Completed NCT01019941 - Pharmacokinetic Study of CKD-810 and Taxotere to Treat Patient With Advanced Solid Cancer Phase 1
Completed NCT02694822 - AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Subjects With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy Phase 1/Phase 2